Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Cellular markers for the diagnosis of Alzheimer's disease and for the progression of Alzheimer's disease

一种阿尔茨海默氏、细胞的技术，应用在疾病诊断、生物测试、生物材料分析等方向，能够解决免疫系统不能提供支持等问题

Active Publication Date: 2017-04-05
YEDA RES & DEV CO LTD +1
View PDF6 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Thus, during old age, when the need for maintenance increases, the aging immune system cannot provide the needed support

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Cellular markers for the diagnosis of Alzheimer's disease and for the progression of Alzheimer's disease
  • Cellular markers for the diagnosis of Alzheimer's disease and for the progression of Alzheimer's disease
  • Cellular markers for the diagnosis of Alzheimer's disease and for the progression of Alzheimer's disease

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0105] Example 1. Precision and Robustness of Results in Healthy Volunteers

[0106] In the study, the distribution of individual markers on total live peripheral blood mononuclear cells (PBMC) was first tested using blood from young, healthy volunteers in order to check the precision and robustness of the measurements, and then Tested in a controlled study comparing Alzheimer's patients with matched age controls.

[0107] Freshly isolated PBMC from healthy volunteers were labeled with fluorescein isothiocyanate (FITC), phycoerythrin (PE), or allophycocyanin (APC) against CD3, CD14, CD19, CD11c, CD34, and CD15. Nuclear antibodies were stained, and the ratio and expression level of each of these markers were analyzed by fluorescence-activated cell sorting (FACS) ( Figures 1A to 1B ).

[0108] Freshly isolated PBMCs from healthy volunteers were double-stained with APC-labeled mononuclear antibodies against CD3 and FITC- or PE-labeled mononuclear antibodies against CD4, CD8, CT...

Embodiment 2

[0112] Example 2. Alzheimer's patients show γδ-T cells and CD14 in PBMC compared to healthy controls + / CD16 + Cells have elevated levels of both.

[0113] The studies described herein were performed using approximately 32 blood samples, approximately half of which were obtained from Alzheimer's patients and half of which were obtained from age-matched healthy volunteers. In addition, seven blood samples from patients with amyotrophic lateral sclerosis (ALS), another neurodegenerative disease, were analyzed. All blood samples were coded and analysis of the results was performed in a blinded fashion.

[0114] Table 2: Differential counts of peripheral monocytes (% of total PBMC)

[0115]

[0116] The proportions of the PBMC population (monocyte-CD14, T-cell-CD13, and B-cell-CD19) as measured by flow cytometry are presented in Table 2, indicating that there were no significant differences between the patients and the healthy controls. difference.

[0117] Flow cytometry ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention provides the use of cellular blood markers for early diagnosis of Alzheimer's disease and for determining the efficacy of treatments for Alzheimer's disease in Alzheimer's patients (ie, monitoring Alzheimer's disease progression). ); and kits for carrying out these methods.

Description

technical field [0001] The present invention relates to methods for early diagnosis of Alzheimer's disease and for monitoring the progression of Alzheimer's disease. Background technique [0002] Neurodegenerative diseases such as Alzheimer's disease (AD), Parkinson's disease or amyotrophic lateral sclerosis (ALS) share causes of neurodegeneration (including axonal damage, apoptosis and glial hyperplasia) with a chronic progressive course. The pathogenesis and pathophysiology of neurodegenerative diseases are very complex and only partially known. Regardless of differences, age is a common risk factor that plays an important role in the pathophysiology of neurodegenerative diseases. Furthermore, there is substantial evidence that excitotoxicity, oxidative stress, protein aggregation, inflammation and apoptosis, among others, are common pathological events that play a role in disease progression. After more than two decades of enormous efforts by the scientific and pharmac...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): G01N33/53
CPCG01N33/5047G01N33/505G01N2800/2821G01N2800/52G01N33/56972G01N2800/50
Inventor M·艾森巴赫-施瓦兹E·尤乐思
Owner YEDA RES & DEV CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com